PNIPAM-based self-developing gel embolism system as well as preparation method and application thereof
By combining PNIPAM-based autoradiographic gel with albumin microspheres, a microsphere-gel dual-scaffold embolization agent with multiple anti-tumor effects is formed, which solves the problems of insufficient embolization and obstructed diffusion of chemotherapy drugs in TACE, and achieves effective embolization of tumors and synergistic anti-tumor therapy.
Patent Information
- Application Number
- CN202511279873.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-09
- Publication Date
- 2025-12-12
AI Technical Summary
In the treatment of primary hepatocellular carcinoma, existing transcatheter arterial chemoembolization (TACE) has limitations. Traditional embolization materials are difficult to effectively embolize the small blood vessels at the tumor terminal. Chemotherapy drugs are prone to burst release, causing systemic toxicity. The tumor microenvironment hinders the diffusion of chemotherapy drugs, and hypoxia exacerbates angiogenesis, resulting in poor treatment outcomes.
A PNIPAM-based autoradiographic gel embolization system was adopted. Poly(N-isopropylacrylamide) modified with triiodobenzoic acid was synthesized by soap-free emulsion polymerization and then combined with albumin microspheres to form a microsphere-gel dual-scaffold embolization agent that combines hypoxia-responsive antitumor drugs and anti-angiogenic drugs, thereby achieving embolization, autoradiography, and hypoxia-enhanced chemotherapy.
It achieves effective embolization of tumor blood vessels, activates chemotherapy drugs under hypoxic conditions, synergistically promotes anti-tumor treatment, improves the tumor microenvironment, enhances the effect of chemotherapy, inhibits angiogenesis, and strengthens the therapeutic effect.